Immunic, Inc. (IMUX)
Immunic chief scientific officer shares insights on innovative MS therapy - ICYMI
To mark World Brain Day on July 22, Immunic Inc (NASDAQ:IMUX)'s chief scientific officer Hella Kohlhof joined Proactive to discuss the company's lead asset vidofludimus calcium which is being developed to treat the neurological disease multiple sclerosis (MS). She highlighted that this drug has a dual mode of action, with neuroprotection, anti-inflammatory, and antiviral properties.
Immunic appoints Simona Skerjanec to board of directors
Biotechnology firm Immunic Inc (NASDAQ:IMUX) announced the appointment of Simona Skerjanec to its board of directors. Skerjanec brings nearly three decades of experience in drug development and commercialization, having held senior roles at top pharmaceutical companies.
Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch
Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal efforts to prepare for the potential launch of vidofludimus calcium. Jason Tardio will join the company in the newly created role of COO and president from July 12, the biotechnology company said.
Immunic is developing a pipeline of oral therapies for chronic inflammatory and autoimmune diseases
Nvidia Corp is set to dominate market discussions this week as it prepares to release its earnings report on Wednesday afternoon. The semiconductor giant, with a market cap of approximately $2.3 trillion, holds significant influence in the S&P 500. Its performance is expected to impact the technology sector and broader market indices. "As Nvidia goes, so go most of the semiconductor stocks and AI plays," is how Jay Woods, chief global strategist at Freedom Capital Markets (NASDAQ:FRHC), put it. He noted that the stock's average post-earnings move is plus 8.5%, making it a critical factor for market volatility. Analysts ratings, based on Bloomberg statistics, have the equivalent of 61 buys, 7 holds and 0 sells on the stock. The average analyst price target is $1018.45 which is less than a 10% upside from current levels. “While a disappointment could open the door for many potential downgrades, a beat should lead to a wave of price target upgrades,” said Woods. Beyond Nvidia, other major earnings include Lowe’s, Target, Toll Brothers, elf Beauty, and Macy’s. Zoom Video and Palo Alto Networks are also in focus, with their earnings reports potentially adding to market movements. Zoom Video, which has been struggling since its peak, needs to show sustained improvement while Palo Alto Networks aims to recover from recent declines despite a strong track record, according to Woods. On the macro front The week also features significant economic data releases. Existing Home Sales and FOMC minutes on Wednesday, Jobless Claims and New Home Sales on Thursday, and Durable Goods and Consumer Sentiment on Friday will provide insights into the economic landscape. The S&P 500 reached new highs last week, driven by a cooler-than-expected CPI number, which fueled optimism about potential Fed rate cuts. However, the 10-year yield remains stable above key technical levels, maintaining caution among traders. Freedom Capital Markets (NASDAQ:FRHC) notes the market's anticipation for the Fed minutes, which will reveal any divisions among committee members regarding future rate hikes or cuts. The consensus is no action in June, with possible rate cuts discussed for July or September. Click here to subscribe to future Freedom weekly newsletters by Jay Woods.
